Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Accured Expenses (2020 - 2025)

Arcutis Biotherapeutics has reported Change in Accured Expenses over the past 6 years, most recently at $23.5 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $23.5 million for Q4 2025, up 77.9% from a year ago — trailing twelve months through Dec 2025 was $50.0 million (up 56.23% YoY), and the annual figure for FY2025 was $50.0 million, up 56.23%.
  • Change in Accured Expenses for Q4 2025 was $23.5 million at Arcutis Biotherapeutics, up from $5.6 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for ARQT hit a ceiling of $23.5 million in Q4 2025 and a floor of -$5.5 million in Q1 2022.
  • Median Change in Accured Expenses over the past 5 years was $4.5 million (2021), compared with a mean of $5.0 million.
  • Biggest five-year swings in Change in Accured Expenses: soared 1711.17% in 2021 and later tumbled 234.77% in 2023.
  • Arcutis Biotherapeutics' Change in Accured Expenses stood at $11.7 million in 2021, then tumbled by 94.73% to $616000.0 in 2022, then surged by 860.55% to $5.9 million in 2023, then soared by 122.8% to $13.2 million in 2024, then skyrocketed by 77.9% to $23.5 million in 2025.
  • The last three reported values for Change in Accured Expenses were $23.5 million (Q4 2025), $5.6 million (Q3 2025), and $21.2 million (Q2 2025) per Business Quant data.